Niu Chuan-Zhen, Zhang Fu-Hua, Li Yan, Liu Jing-Jing, Bao Cui-Xia

Language: English
References: 30
Page: 992-1000
PDF size: 205.32 Kb.

ABSTRACT

Introduction and aim. Hepatocellular carcinoma (HCC) is a lethal malignancy, but the molecular mechanisms of hepatocarcinogenesis remain undefined. The present study aims to investigate the relationship between polymorphisms of the hepatic lipase (HL) gene promoters and risk of HCC. Material and methods. Totally, 279 HCC patients and 200 healthy individuals were enrolled. Polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) was used to analyze the genotypes of HL gene. Logistic regression analysis was conducted to identify risk factors of HCC. Results. There was significant difference in the distribution of smoking history, drinking history, and family history of subjects between the case and control groups (all p ‹ 0.05). Difference in the -250G/A (p = 0.011; OR = 1.61; 95%CI: 1.11-2.34) and -514C/T (p = 0.007; OR = 1.65; 95%CI: 1.14-2.38) genotypes and allele frequencies between two groups was significant. A higher risk of HCC was identified in those with polymorphisms in the - 250G/A (p = 0.007; OR = 1.45; 95%CI: 1.11-1.89) and -514C/T (p = 0.003; OR = 1.51; 95%CI: 1.15-2.00). Polymorphisms at - 250G/A (GA + AA) (p = 0.025; OR = 1.55; 95%CI: 1.06-2.28), -514C/T (CT + TT) (p = 0.021; OR = 1.57; 95%CI: 1.07-2.29), smoking history (p = 0.017; OR = 1.70; 95%CI: 1.10-2.63) and drinking history (p = 0.003; OR = 2.04; 95%CI: 1.27-3.27) were significantly related to the risk of HCC (all p ‹ 0.05). Conclusion. The results obtained from this study indicated that polymorphisms of -250G/A and -514C/T in HL gene promoters were associated with the risk of HCC.

REFERENCES

1. Chou YE, Hsieh MJ, Chiou HL, Lee HL, Yang SF, Chen TY. CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. Biomed Res Int 2014; 2014: 231474.

2. El-Din HG, Ghafar NA, Saad NE, Aziz M, Rasheed D, Hassan EM. Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinoma. Arch Med Sci 2010; 6: 348-55.

3. Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, Zhou T, et al. Rho kinase phosphorylation promotes ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res 2011; 71: 1721-9.

4. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010; 36: 43-53.

5. Koh WP, Robien K, Wang R, Govindarajan S, Yuan JM, Yu MC. Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study. Br J Cancer 2011; 105: 1430-5.

6. Siegel AB, Conner K, Wang S, Jacobson JS, Hershman DL, Hidalgo R, Verna EC, et al. Smoking and hepatocellular carcinoma mortality. Exp Ther Med 2012; 3: 124-8.

7. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 2013; 58: 1693-702.

8. Lu SC, Zhong JH, Tan JT, Tang HL, Liu XG, Xiang BD, Li LQ, et al. Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis. BMJ Open 2015; 5: e008263.

9. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013; 368: 2266-76.

10. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012; 142: 957-66 e12.

11. Pravica V, Popadic D, Savic E, Markovic M, Drulovic J, Mostarica- Stojkovic M. Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers. Immunol Res 2012; 52: 42-52.

12. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998; 280: 1077-82.

13. Dichek HL, Brecht W, Fan J, Ji ZS, McCormick SP, Akeefe H, Conzo L, et al. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J Biol Chem 1998; 273: 1896-903.

14. van’t Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A. Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Arterioscler Thromb Vasc Biol 2000; 20: 1335-9.

15. Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 2013; 73: 4992-5002.

16. Gong J, Lv L, Huo J. Roles of F-box proteins in human digestive system tumors (Review). Int J Oncol 2014; 45: 2199- 207.

17. Chen M, Therneau T, Orsini LS, Qiao YL. Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. BMC Gastroenterol 2011; 11: 53.

18. Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, Yeh YH, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010; 17: 1808-15.

19. Guan Q, Chen Z, Chen Q, Zhi X. XRCC1 and XPD polymorphisms and their relation to the clinical course in hepatocarcinoma patients. Oncol Lett 2017; 14: 2783-8.

20. Chen CT, Liao WY, Hsu CC, Hsueh KC, Yang SF, Teng YH, Yu YL. FUT2 genetic variants as predictors of tumor development with hepatocellular carcinoma. Int J Med Sci 2017; 14: 885-90.

21. Leonhardt U, Ritzel U, Ottleben M, Ramadori G. Circulating human hepatic lipase mRNA in patients with hepatocellular carcinoma and healthy controls. Eur J Surg 1999; 165: 539-42.

22. Dichek HL, Agrawal N, El Andaloussi N, Qian K. Attenuated corticosterone response to chronic ACTH stimulation in hepatic lipase-deficient mice: evidence for a role for hepatic lipase in adrenal physiology. Am J Physiol Endocrinol Metab 2006; 290: E908-15.

23. Erickson B, Selvan SP, Ko KW, Kelly K, Quiroga AD, Li L, Nelson R, et al. Endoplasmic reticulum-localized hepatic lipase decreases triacylglycerol storage and VLDL secretion. Biochim Biophys Acta 2013; 1831: 1113-23.

24. Ou L, Yao L, Guo Y, Fan S. Association of the G-250A promoter polymorphism in the hepatic lipase gene with the risk of type 2 diabetes mellitus. Ann Endocrinol (Paris) 2013; 74: 45-8.

25. Faggin E, Zambon A, Puato M, Deeb SS, Bertocco S, Sartore S, Crepaldi G, et al. Association between the —514 C→ T polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis. J Am Coll Cardiol 2002; 40: 1059-66.

26. Jiang SS, Weng DS, Jiang L, Zhang YJ, Pan K, Pan QZ, Chen CL, et al. The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. J Cancer 2016; 7: 626-32.

27. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99: 1959-64.

28. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998; 18: 1723-9.

29. Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging 2013; 12: 530-47.

30. Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, Kanematsu T, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 1992; 51: 509-14.